2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782/ https://www.ncbi.nlm.nih.gov/pubmed/31857443 http://dx.doi.org/10.2337/dci19-0066 |
_version_ | 1783489781424979968 |
---|---|
author | Buse, John B. Wexler, Deborah J. Tsapas, Apostolos Rossing, Peter Mingrone, Geltrude Mathieu, Chantal D’Alessio, David A. Davies, Melanie J. |
author_facet | Buse, John B. Wexler, Deborah J. Tsapas, Apostolos Rossing, Peter Mingrone, Geltrude Mathieu, Chantal D’Alessio, David A. Davies, Melanie J. |
author_sort | Buse, John B. |
collection | PubMed |
description | The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA(1c) or individualized HbA(1c) target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min(–1) [1.73 m](–2) or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death. |
format | Online Article Text |
id | pubmed-6971782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-69717822021-02-01 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Buse, John B. Wexler, Deborah J. Tsapas, Apostolos Rossing, Peter Mingrone, Geltrude Mathieu, Chantal D’Alessio, David A. Davies, Melanie J. Diabetes Care Consensus Report Update The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA(1c) or individualized HbA(1c) target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min(–1) [1.73 m](–2) or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death. American Diabetes Association 2020-02 2019-12-19 /pmc/articles/PMC6971782/ /pubmed/31857443 http://dx.doi.org/10.2337/dci19-0066 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
spellingShingle | Consensus Report Update Buse, John B. Wexler, Deborah J. Tsapas, Apostolos Rossing, Peter Mingrone, Geltrude Mathieu, Chantal D’Alessio, David A. Davies, Melanie J. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title_full | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title_fullStr | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title_full_unstemmed | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title_short | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
title_sort | 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd) |
topic | Consensus Report Update |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782/ https://www.ncbi.nlm.nih.gov/pubmed/31857443 http://dx.doi.org/10.2337/dci19-0066 |
work_keys_str_mv | AT busejohnb 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT wexlerdeborahj 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT tsapasapostolos 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT rossingpeter 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT mingronegeltrude 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT mathieuchantal 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT dalessiodavida 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd AT daviesmelaniej 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd |